Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.

You may also be interested in...



Committee Recommends Sanofi’s Multaq For Approval

Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.

Committee Recommends Sanofi’s Multaq For Approval

Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.

Rivaroxaban Committee Review May Hinge On Concerns About Off-Label Use

J&J’s oral anticoagulant Xarelto has solid, but not strong, data for limited surgery claims; bleeding is among the safety worries.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel